<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825785</url>
  </required_header>
  <id_info>
    <org_study_id>20060221</org_study_id>
    <nct_id>NCT01825785</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled, ascending multiple dose
      study assesses the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      subcutaneous administration of 6 doses of 1 mg/kg AMG 785 once every 2 weeks or 3 doses of 3
      mg/kg AMG 785 every 4 weeks in healthy men or postmenopausal women with low bone mass and 3
      doses of 2 mg/kg AMG 785 every 4 weeks or 6 doses of 2 mg/kg AMG 785 every 2 weeks in
      healthy postmenopausal women with low bone mass.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number (percent) of subjects reporting treatment-emergent adverse events</measure>
    <time_frame>169 days following initial investigational product administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number (percent) of subjects who experienced clinically significant changes in safety laboratory tests, physical examinations, vital signs, or electrocardiograms</measure>
    <time_frame>169 days following initial investigational product administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number (percent) of subjects who developed antibodies to AMG 785</measure>
    <time_frame>169 days following initial investigational product administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC), maximum observed concentration (Cmax), and time of maximum drug concentration (Tmax)</measure>
    <time_frame>169 days following initial investigational product administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density as assessed by dual energy X-ray absorptiometry, serum procollagen type 1 N-terminal propeptide, osteocalcin, bone-specific alkaline phosphatase, serum CTX, intact Parathyroid Hormone, serum and ionized calcium, and sclerostin levels</measure>
    <time_frame>169 days following initial investigational product administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Postmenopausal</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 6 doses of 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 3 doses of 3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 6 doses of 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 3 doses of 2 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Interval 1</intervention_name>
    <description>Dose every 2 weeks</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Interval 2</intervention_name>
    <description>Dose every 4 weeks</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females between 45 to 80 years of age

          -  Postmenopausal females

          -  Low bone mineral density

          -  25-hydroxyvitamin D ≥ 20 ng/mL

          -  Weight ≤ 98 kg (216 lb) and/or height ≤ 196 cm (77 in)

        Exclusion Criteria:

          -  Osteoporosis

          -  Subjects with fewer than 2 evaluable (by DXA) vertebrae; metal in hips bilaterally
             that would not allow for at least one evaluable (by DXA) hip; metal in forearms
             bilaterally that would not allow for at least one evaluable (by DXA) forearm

          -  Previous exposure to AMG 785
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 3, 2013</lastchanged_date>
  <firstreceived_date>January 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
